Krystal Biotech, Inc.
KRYS
$193.84
-$6.13-3.07%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 373.16M | 359.21M | 333.45M | 290.51M | 241.52M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 373.16M | 359.21M | 333.45M | 290.51M | 241.52M |
| Cost of Revenue | 21.41M | 23.83M | 22.67M | 20.06M | 17.98M |
| Gross Profit | 351.76M | 335.38M | 310.78M | 270.45M | 223.54M |
| SG&A Expenses | 136.75M | 127.84M | 120.31M | 113.65M | 107.12M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 214.93M | 207.37M | 199.85M | 187.28M | 176.53M |
| Operating Income | 158.24M | 151.84M | 133.59M | 103.23M | 64.99M |
| Income Before Tax | 186.95M | 168.75M | 138.02M | 95.36M | 57.40M |
| Income Tax Expenses | -11.96M | 22.03M | 14.06M | 6.20M | 5.03M |
| Earnings from Continuing Operations | 198.91 | 146.73 | 123.96 | 89.16 | 52.37 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 198.91M | 146.73M | 123.96M | 89.16M | 52.37M |
| EBIT | 158.24M | 151.84M | 133.59M | 103.23M | 64.99M |
| EBITDA | 159.56M | 153.20M | 135.95M | 105.70M | 68.08M |
| EPS Basic | 6.89 | 5.09 | 4.31 | 3.11 | 1.83 |
| Normalized Basic EPS | 4.05 | 3.93 | 3.55 | 2.90 | 2.08 |
| EPS Diluted | 6.68 | 4.93 | 4.17 | 3.00 | 1.77 |
| Normalized Diluted EPS | 3.92 | 3.80 | 3.41 | 2.79 | 2.00 |
| Average Basic Shares Outstanding | 115.43M | 115.20M | 114.88M | 114.36M | 113.78M |
| Average Diluted Shares Outstanding | 119.34M | 119.41M | 119.29M | 118.71M | 117.65M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |